Effects of specific inhibition of cyclo‐oxygenase‐1 and cyclo‐oxygenase‐2 in the rat stomach with normal mucosa and after acid challenge
- 1 April 2001
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 132 (7) , 1565-1573
- https://doi.org/10.1038/sj.bjp.0703955
Abstract
Effects of the cyclo‐oxygenase (COX)‐1 inhibitor SC‐560 and the COX‐2 inhibitors rofecoxib and DFU were investigated in the normal stomach and after acid challenge. In healthy rats, neither SC‐560 nor rofecoxib (20 mg kg−1 each) given alone damaged the mucosa. Co‐treatment with SC‐560 and rofecoxib, however, induced severe lesions comparable to indomethacin (20 mg kg−1) whereas co‐administration of SC‐560 and DFU (20 mg kg−1 each) had no comparable ulcerogenic effect 5 h after dosing. SC‐560 (20 mg kg−1) inhibited gastric 6‐keto‐prostaglandin (PG) F1α by 86±5% and platelet thromboxane (TX) B2 formation by 89±4% comparable to indomethacin (20 mg kg−1). Rofecoxib (20 mg kg−1) did not inhibit gastric and platelet eicosanoids. Intragastric HCl elevated mucosal mRNA levels of COX‐2 but not COX‐1. Dexamethasone (2 mg kg−1) prevented the up‐regulation of COX‐2. After acid challenge, SC‐560 (5 and 20 mg kg−1) induced dose‐dependent injury. Rofecoxib (20 mg kg−1), DFU (5 mg kg−1) and dexamethasone (2 mg kg−1) given alone were not ulcerogenic but aggravated SC‐560‐induced damage. DFU augmented SC‐560 damage 1 but not 5 h after administration whereas rofecoxib increased injury after both treatment periods suggesting different time courses. Gastric injurious effects of rofecoxib and DFU correlated with inhibition of inflammatory PGE2. The findings show that in the normal stomach lesions only develop when both COX‐1 and COX‐2 are inhibited. In contrast, during acid challenge inhibition of COX‐1 renders the mucosa more vulnerable suggesting an important role of COX‐1 in mucosal defence in the presence of a potentially noxious agent. In this function COX‐1 is supported by COX‐2. In the face of pending injury, however, COX‐2 cannot maintain mucosal integrity when the activity of COX‐1 is suppressed. British Journal of Pharmacology (2001) 132, 1565–1573; doi:10.1038/sj.bjp.0703955Keywords
This publication has 37 references indexed in Scilit:
- NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesionsPublished by Elsevier ,2002
- Effect of SC-560, a selective cyclooxygenase (COX)-1 inhibitor, and its modification by COX-2 inhibition in the rat stomachGastroenterology, 2000
- Effects of inhibition of prostaglandin endoperoxide synthase‐2 in chronic gastro‐intestinal ulcer models in ratsBritish Journal of Pharmacology, 1998
- Multiple Female Reproductive Failures in Cyclooxygenase 2–Deficient MicePublished by Elsevier ,1997
- Induction of cyclooxygenase 1 and 2 in the rat stomach during endotoxemia: Role in resistance to damageGastroenterology, 1997
- Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitorBritish Journal of Pharmacology, 1997
- The macula densa: recent developmentsJournal Of Hypertension, 1996
- Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulcerationCell, 1995
- Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouseCell, 1995
- Expression of mRNA for cyclooxygenase‐1 and cyclooxygenase‐2 in human tissuesFEBS Letters, 1993